Radiobotics releases RBfracture 2.4 with performance improvements for paediatric and adult patients

RBfracture 2.4™ brings a series of performance enhancements aimed at increasing diagnostic accuracy while maintaining fast analysis times and low hardware requirements.

March 27, 2025 — Copenhagen, Denmark — Radiobotics, a pioneering leader in AI-driven radiology solutions, is pleased to announce the release of RBfracture 2.4, now available to customers and partners. The latest update brings a series of performance enhancements aimed at increasing diagnostic accuracy while maintaining fast analysis times and low hardware requirements.

This release focuses on reducing false positives, particularly in paediatric patients, an area where misinterpretation on musculoskeletal X-rays is common — especially by emergency clinicians.

RBfracture 2.4 performance improvements

One of the key improvements addresses how RBfracture distinguishes epiphyseal lines, the naturally occurring growth plates in children’s bones. These radiolucent lines often resemble fractures and can be flagged incorrectly by both AI tools and clinicians.

By refining RBfracture’s understanding of these features, RBfracture 2.4 achieves a >25% relative reduction in false positives in paediatric cases. Further performance upgrades also resulted in a >10% reduction in false negatives in adult patients.

These improvements enhance clinical confidence in the tool and support more efficient patient care.

Importantly, these performance improvements do not impact RBfracture’s processing speed or computing requirements, ensuring a seamless upgrade experience for existing customers.

“Our latest release is the result of ongoing collaboration with clinical partners and feedback from frontline users,” said Mads Jarner Brevadt, COO and co-founder of Radiobotics. “By improving performance in complex cases — especially in children — we’re continuing to make RBfracture even more reliable and supportive for Emergency and Radiology.”

About Radiobotics

Founded in 2017, Radiobotics, a Medimaps Group company, is an award-winning Danish MedTech company dedicated to advancing musculoskeletal (MSK) radiology with AI-powered solutions. Radiobotics’ flagship solution, RBfracture™, is designed to support Emergency and Radiology with highly accurate detection of trauma-related findings, including fractures, dislocations, lipohemarthrosis, and effusion.

Radiobotics’ commitment to delivering precise, expert-level care in MSK imaging 24/7, regardless of time, infrastructure, or staffing constraints, constraints, is reflected in its close collaboration with leading clinical institutions, including partnering with Oxford University Hospital (OUH) on the world’s first and largest randomised clinical trial evaluating radiology AI in urgent care as well as achieving NICE approval for use in urgent care settings across the NHS.

Media contact
Elyse Sims
Head of Marketing, Radiobotics

Share this press release

Latest news